<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35213988</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">1999-4923</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>14</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutics</Title>
          <ISOAbbreviation>Pharmaceutics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacophore-Based Discovery of Substrates of a Novel Drug/Proton-Antiporter in the Human Brain Endothelial hCMEC/D3 Cell Line.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">255</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics14020255</ELocationID>
        <Abstract>
          <AbstractText>A drug/proton-antiporter, whose the molecular structure is still unknown, was previously evidenced at the blood-brain barrier (BBB) by functional experiments. The computational method could help in the identification of substrates of this solute carrier (SLC) transporter. Two pharmacophore models for substrates of this transporter using the FLAPpharm approach were developed. The trans-stimulation potency of 40 selected compounds for already known specific substrates ([<sup>3</sup>H]-clonidine) were determined and compared in the human brain endothelial cell line hCMEC/D3. Results. The two pharmacophore models obtained were used as templates to screen xenobiotic and endogenous compounds from four databases (e.g., Specs), and 45 hypothetical new candidates were tested to determine their substrate capacity. Psychoactive drugs such as antidepressants (e.g., imipramine, desipramine), antipsychotics/neuroleptics such as phenothiazine derivatives (chlorpromazine), sedatives anti-histamine-H<sub>1</sub> drugs (promazine, promethazine, triprolidine, pheniramine), opiates/opioids (e.g., hydrocodone), trihexyphenidyl and sibutramine were correctly predicted as proton-antiporter substrates. The best performing pharmacophore model for the proton-antiporter substrates appeared as a good predictor of known substrates and allowed the identification of new substrate compounds. This model marks a new step in the characterization of this drug/proton-antiporter and will be of great use in uncovering its substrates and designing chemical entities with an improved influx capability to cross the BBB.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Smirnova</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goracci</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-9282-9013</Identifier>
            <AffiliationInfo>
              <Affiliation>Biology and Biotechnology, Department of Chemistry, University of Perugia, 06123 Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cruciani</LastName>
            <ForeName>Gabriele</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Biology and Biotechnology, Department of Chemistry, University of Perugia, 06123 Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Federici</LastName>
            <ForeName>Laetitia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Declèves</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-9526-2294</Identifier>
            <AffiliationInfo>
              <Affiliation>Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Biologie du Médicament et Toxicologie, AP-HP, Hôpital Cochin, 75014 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chapy</LastName>
            <ForeName>Hélène</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cisternino</LastName>
            <ForeName>Salvatore</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8500-3574</Identifier>
            <AffiliationInfo>
              <Affiliation>Université de Paris, INSERM UMR_S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Service Pharmacie, AP-HP, Hôpital Necker-Enfants Malades, 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharmaceutics</MedlineTA>
        <NlmUniqueID>101534003</NlmUniqueID>
        <ISSNLinking>1999-4923</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">FLAPpharm approach</Keyword>
        <Keyword MajorTopicYN="N">biological transport</Keyword>
        <Keyword MajorTopicYN="N">blood-brain barrier</Keyword>
        <Keyword MajorTopicYN="N">computational chemistry</Keyword>
        <Keyword MajorTopicYN="N">drug delivery</Keyword>
        <Keyword MajorTopicYN="N">in silico</Keyword>
        <Keyword MajorTopicYN="N">pharmacophore-based substrate discovery</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>1</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35213988</ArticleId>
        <ArticleId IdType="pmc">PMC8875908</ArticleId>
        <ArticleId IdType="doi">10.3390/pharmaceutics14020255</ArticleId>
        <ArticleId IdType="pii">pharmaceutics14020255</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010;37:13–25. doi: 10.1016/j.nbd.2009.07.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2009.07.030</ArticleId>
            <ArticleId IdType="pubmed">19664713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaves C., Remião F., Cisternino S., Decleves X. Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain. Curr. Neuropharmacol. 2017;15:1156–1173. doi: 10.2174/1570159X15666170504095823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X15666170504095823</ArticleId>
            <ArticleId IdType="pmc">PMC5725546</ArticleId>
            <ArticleId IdType="pubmed">28474563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samodelov S.L., Kullak-Ublick G.A., Gai Z., Visentin M. Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology. Int. J. Mol. Sci. 2020;21:7890.  doi: 10.3390/ijms21217890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21217890</ArticleId>
            <ArticleId IdType="pmc">PMC7660683</ArticleId>
            <ArticleId IdType="pubmed">33114309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaves C., Campanelli F., Chapy H., Gomez-Zepeda D., Glacial F., Smirnova M., Taghi M., Pallud J., Perrière N., Declèves X., et al.  An Interspecies Molecular and Functional Study of Organic Cation Transporters at the Blood-Brain Barrier: From Rodents to Humans. Pharmaceutics. 2020;12:308.  doi: 10.3390/pharmaceutics12040308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics12040308</ArticleId>
            <ArticleId IdType="pmc">PMC7238036</ArticleId>
            <ArticleId IdType="pubmed">32231079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>André P., Saubamea B., Cochois-Guégan V., Marie-Claire C., Cattelotte J., Smirnova M., Schinkel A.H., Scherrmann J.-M., Cisternino S. Transport of Biogenic Amine Neurotransmitters at the Mouse Blood–Retina and Blood–Brain Barriers by Uptake1 and Uptake2. J. Cereb. Blood Flow Metab. 2012;32:1989–2001. doi: 10.1038/jcbfm.2012.109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jcbfm.2012.109</ArticleId>
            <ArticleId IdType="pmc">PMC3493996</ArticleId>
            <ArticleId IdType="pubmed">22850405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>César-Razquin A., Snijder B., Frappier-Brinton T., Isserlin R., Gyimesi G., Bai X., Reithmeier R.A., Hepworth D., Hediger M.A., Edwards A.M., et al.  A Call for Systematic Research on Solute Carriers. Cell. 2015;162:478–487. doi: 10.1016/j.cell.2015.07.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.07.022</ArticleId>
            <ArticleId IdType="pubmed">26232220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Superti-Furga G., Lackner D., Wiedmer T., Ingles-Prieto A., Barbosa B., Girardi E., Goldmann U., Gürtl B., Klavins K., Klimek C., et al.  The RESOLUTE consortium: Unlocking SLC transporters for drug discovery. Nat. Rev. Drug Discov. 2020;19:429–430. doi: 10.1038/d41573-020-00056-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41573-020-00056-6</ArticleId>
            <ArticleId IdType="pubmed">32265506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>André P., Debray M., Scherrmann J.-M., Cisternino S. Clonidine Transport at the Mouse Blood—Brain Barrier by a New H+ Antiporter that Interacts with Addictive Drugs. J. Cereb. Blood Flow Metab. 2009;29:1293–1304. doi: 10.1038/jcbfm.2009.54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jcbfm.2009.54</ArticleId>
            <ArticleId IdType="pubmed">19458607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapy H., Goracci L., Vayer P., Parmentier Y., Carrupt P.-A., Decleves X., Scherrmann J.-M., Cisternino S., Cruciani G. Pharmacophore-based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell line. Br. J. Pharmacol. 2015;172:4888–4904. doi: 10.1111/bph.13258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.13258</ArticleId>
            <ArticleId IdType="pmc">PMC4621989</ArticleId>
            <ArticleId IdType="pubmed">26220580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auvity S., Chapy H., Goutal S., Caillé F., Hosten B., Smirnova M., Decleves X., Tournier N., Cisternino S. Diphenhydramine as a selective probe to study H+-antiporter function at the blood–brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging. J. Cereb. Blood Flow Metab. 2016;37:2185–2195. doi: 10.1177/0271678X16662042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0271678X16662042</ArticleId>
            <ArticleId IdType="pmc">PMC5464711</ArticleId>
            <ArticleId IdType="pubmed">27488910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapy H., Smirnova M., André P., Schlatter J., Chiadmi F., Couraud P.-O., Scherrmann J.-M., Decleves X., Cisternino S. Carrier-Mediated Cocaine Transport at the Blood-Brain Barrier as a Putative Mechanism in Addiction Liability. Int. J. Neuropsychopharmacol. 2014;18:pyu001. doi: 10.1093/ijnp/pyu001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ijnp/pyu001</ArticleId>
            <ArticleId IdType="pmc">PMC4368859</ArticleId>
            <ArticleId IdType="pubmed">25539501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cisternino S., Chapy H., André P., Smirnova M., Debray M., Scherrmann J.-M. Coexistence of Passive and Proton Antiporter-Mediated Processes in Nicotine Transport at the Mouse Blood–Brain Barrier. AAPS J. 2012;15:299–307. doi: 10.1208/s12248-012-9434-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12248-012-9434-6</ArticleId>
            <ArticleId IdType="pmc">PMC3675746</ArticleId>
            <ArticleId IdType="pubmed">23212563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okura T., Hattori A., Takano Y., Sato T., Hammarlund-Udenaes M., Terasaki T., Deguchi Y. Involvement of the Pyrilamine Transporter, a Putative Organic Cation Transporter, in Blood-Brain Barrier Transport of Oxycodone. Drug Metab. Dispos. 2008;36:2005–2013. doi: 10.1124/dmd.108.022087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.108.022087</ArticleId>
            <ArticleId IdType="pubmed">18606742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg M.J., Spector R., Chiang C.K. Transport of diphenhydramine in the central nervous system. J. Pharmacol. Exp. Ther. 1987;240:717–722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3559970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Qi B., Su H., Li J., Sun X., He Q., Fu Y., Zhang Z. Pyrilamine-sensitive proton-coupled organic cation (H+/OC) antiporter for brain-specific drug delivery. J. Control. Release. 2017;254:34–43. doi: 10.1016/j.jconrel.2017.03.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2017.03.034</ArticleId>
            <ArticleId IdType="pubmed">28351667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Au-Yeung S.C.S., Rurak D.W., Gruber N., Riggs K.W. A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: Potential involvement of a carrier-mediated mechanism. Drug Metab. Dispos. 2006;34:955–960. doi: 10.1124/dmd.105.007898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.105.007898</ArticleId>
            <ArticleId IdType="pubmed">16510542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sachkova A., Doetsch D.A., Jensen O., Brockmöller J., Ansari S. How do psychostimulants enter the human brain? Analysis of the role of the proton-organic cation antiporter. Biochem. Pharmacol. 2021;192:114751. doi: 10.1016/j.bcp.2021.114751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2021.114751</ArticleId>
            <ArticleId IdType="pubmed">34464621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapy H., Saubamea B., Tournier N., Bourasset F., Behar-Cohen F., Decleves X., Scherrmann J.-M., Cisternino S. Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier. Br. J. Pharmacol. 2016;173:497–510. doi: 10.1111/bph.13376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.13376</ArticleId>
            <ArticleId IdType="pmc">PMC4728421</ArticleId>
            <ArticleId IdType="pubmed">26507673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W., Metzner L., Hoffmann K., Neubert R.H.H., Brandsch M. Substrate Specificity and Mechanism of the Intestinal Clonidine Uptake by Caco-2 Cells. Pharm. Res. 2006;23:131–137. doi: 10.1007/s11095-005-8925-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-005-8925-x</ArticleId>
            <ArticleId IdType="pubmed">16333714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapy H., André P., Decleves X., Scherrmann J.-M., Cisternino S. A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier. Br. J. Pharmacol. 2015;172:4714–4725. doi: 10.1111/bph.13246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.13246</ArticleId>
            <ArticleId IdType="pmc">PMC4594274</ArticleId>
            <ArticleId IdType="pubmed">26177775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwayama K., Inoue H., Kanamori T., Tsujikawa K., Miyaguchi H., Iwata Y., Miyauchi S., Kamo N., Kishi T. Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells. Biochim. Biophys. Acta. 2008;1778:42–50. doi: 10.1016/j.bbamem.2007.08.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2007.08.023</ArticleId>
            <ArticleId IdType="pubmed">17936243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuuchi H., Katsura T., Saito H., Hashimoto Y., Inui K.I. Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: Contribution of pH-dependent transport system. J. Pharmacol. Exp. Ther. 1999;290:388–392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10381804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross S., Baroni M., Goracci L., Cruciani G. GRID-Based Three-Dimensional Pharmacophores I: FLAPpharm, a Novel Approach for Pharmacophore Elucidation. J. Chem. Inf. Model. 2012;52:2587–2598. doi: 10.1021/ci300153d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ci300153d</ArticleId>
            <ArticleId IdType="pubmed">22970894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goracci L., Buratta S., Urbanelli L., Ferrara G., Di Guida R., Emiliani C., Cross S. Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. Eur. J. Med. Chem. 2015;92:49–63. doi: 10.1016/j.ejmech.2014.12.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2014.12.028</ArticleId>
            <ArticleId IdType="pubmed">25544686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sirci F., Goracci L., Rodríguez D., Van Muijlwijk-Koezen J., de Terán H.G., Mannhold R. Ligand-, structure- and pharmacophore-based molecular fingerprints: A case study on adenosine A1, A2A, A2B, and A3 receptor antagonists. J. Comput. Aided Mol. Des. 2012;26:1247–1266. doi: 10.1007/s10822-012-9612-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10822-012-9612-8</ArticleId>
            <ArticleId IdType="pubmed">23065321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez C.P., Rohrbach P., McLean J.E., Fidock D.A., Stein W.D., Lanzer M. Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum. Mol. Microbiol. 2007;64:407–420. doi: 10.1111/j.1365-2958.2007.05664.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2958.2007.05664.x</ArticleId>
            <ArticleId IdType="pmc">PMC2944662</ArticleId>
            <ArticleId IdType="pubmed">17493125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dresser M.J., Gray A.T., Giacomini K.M. Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1) J. Pharmacol. Exp. Ther. 2000;292:1146–1152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10688634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geier E.G., Schlessinger A., Fan H., Gable J.E., Irwin J., Sali A., Giacomini K.M. Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proc. Natl. Acad. Sci. USA. 2013;110:5480–5485. doi: 10.1073/pnas.1218165110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1218165110</ArticleId>
            <ArticleId IdType="pmc">PMC3619328</ArticleId>
            <ArticleId IdType="pubmed">23509259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shafik S.H., Cobbold S.A., Barkat K., Richards S.N., Lancaster N.S., Llinás M., Hogg S.J., Summers R.L., McConville M.J., Martin R.E. The natural function of the malaria parasite’s chloroquine resistance transporter. Nat. Commun. 2020;11:3922. doi: 10.1038/s41467-020-17781-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-17781-6</ArticleId>
            <ArticleId IdType="pmc">PMC7413254</ArticleId>
            <ArticleId IdType="pubmed">32764664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baroni M., Cruciani G., Sciabola S., Perruccio F., Mason J.S. A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application. J. Chem. Inf. Model. 2007;47:279–294. doi: 10.1021/ci600253e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ci600253e</ArticleId>
            <ArticleId IdType="pubmed">17381166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milletti F., Storchi L., Goracci L., Bendels S., Wagner B., Kansy M., Cruciani G. Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series. Eur. J. Med. Chem. 2010;45:4270–4279. doi: 10.1016/j.ejmech.2010.06.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2010.06.026</ArticleId>
            <ArticleId IdType="pubmed">20633962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruciani G., Crivori P., Carrupt P.-A., Testa B. Molecular fields in quantitative structure–permeation relationships: The VolSurf approach. J. Mol. Struct. Theochem. 2000;503:17–30. doi: 10.1016/S0166-1280(99)00360-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0166-1280(99)00360-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sedykh A., Fourches D., Duan J., Hucke O., Garneau M., Zhu H., Bonneau P., Tropsha A. Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm. Res. 2012;30:996–1007. doi: 10.1007/s11095-012-0935-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-012-0935-x</ArticleId>
            <ArticleId IdType="pmc">PMC3596480</ArticleId>
            <ArticleId IdType="pubmed">23269503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiele I., Swainston N., Fleming R.M., Hoppe A., Sahoo S., Aurich M.K., Haraldsdottir H., Mo M.L., Rolfsson Ó., Stobbe M.D., et al.  A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 2013;31:419–425. doi: 10.1038/nbt.2488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2488</ArticleId>
            <ArticleId IdType="pmc">PMC3856361</ArticleId>
            <ArticleId IdType="pubmed">23455439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wishart D.S., Jewison T., Guo A.C., Wilson M., Knox C., Liu Y., Djoumbou Y., Mandal R., Aziat F., Dong E., et al.  HMDB 3.0—The Human Metabolome Database in 2013. Nucleic Acids Res. 2013;41:D801–D807. doi: 10.1093/nar/gks1065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gks1065</ArticleId>
            <ArticleId IdType="pmc">PMC3531200</ArticleId>
            <ArticleId IdType="pubmed">23161693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goracci L., Deschamps N., Randazzo G.M., Petit C., Passos C.D.S., Carrupt P.-A., Simões-Pires C., Nurisso A. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors. Sci. Rep. 2016;6:29086. doi: 10.1038/srep29086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep29086</ArticleId>
            <ArticleId IdType="pmc">PMC4941420</ArticleId>
            <ArticleId IdType="pubmed">27404291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tosco P., Mackey M.  Comprehensive Medicinal Chemistry III. Elsevier; Amsterdam, The Netherlands: 2017. Lessons and Successes in the Use of Molecular Fields; pp. 253–296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/b978-0-12-409547-2.12353-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triballeau N., Acher F., Brabet I., Pin J.-P., Bertrand H.-O. Virtual Screening Workflow Development Guided by the “Receiver Operating Characteristic” Curve Approach. Application to High-Throughput Docking on Metabotropic Glutamate Receptor Subtype 4. J. Med. Chem. 2005;48:2534–2547. doi: 10.1021/jm049092j.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm049092j</ArticleId>
            <ArticleId IdType="pubmed">15801843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammarlund-Udenaes M., Fridén M., Syvänen S., Gupta A. On The Rate and Extent of Drug Delivery to the Brain. Pharm. Res. 2007;25:1737–1750. doi: 10.1007/s11095-007-9502-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-007-9502-2</ArticleId>
            <ArticleId IdType="pmc">PMC2469271</ArticleId>
            <ArticleId IdType="pubmed">18058202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Summerfield S.G., Zhang Y., Liu H. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier. J. Pharmacol. Exp. Ther. 2016;358:294–305. doi: 10.1124/jpet.116.232447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.116.232447</ArticleId>
            <ArticleId IdType="pubmed">27194478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., Chen C., Chen X., Choo E., Cianfrogna J., et al.  The impact of P-Glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the mdr1a/1B knockout mouse model. Drug Metab. Dispos. 2004;33:165–174. doi: 10.1124/dmd.104.001230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.104.001230</ArticleId>
            <ArticleId IdType="pubmed">15502009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaffer C.L., Osgood S.M., Mancuso J.Y., Doran A.C. Diphenhydramine has Similar Interspecies Net Active Influx at the Blood–Brain Barrier. J. Pharm. Sci. 2014;103:1557–1562. doi: 10.1002/jps.23927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.23927</ArticleId>
            <ArticleId IdType="pubmed">24633923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadiq M.W., Boström E., Keizer R., Bjorkman S., Hammarlund-Udenaes M. Oxymorphone Active Uptake at the Blood–Brain Barrier and Population Modeling of its Pharmacokinetic–Pharmacodynamic Relationship. J. Pharm. Sci. 2013;102:3320–3331. doi: 10.1002/jps.23492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.23492</ArticleId>
            <ArticleId IdType="pubmed">23463542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verbeek J., Syvänen S., Schuit R.C., Eriksson J., de Lange E.C., Windhorst A.D., Luurtsema G., Lammertsma A.A. Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil. Nucl. Med. Biol. 2012;39:530–539. doi: 10.1016/j.nucmedbio.2011.10.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nucmedbio.2011.10.017</ArticleId>
            <ArticleId IdType="pubmed">22226023</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
